Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

Cancer-associated fibroblasts (CAFs) play an important role in metastatic melanoma, and an enhanced understanding of that role could lead to important new therapeutic pathways, according to a new ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

enhance the immune system’s ability to fight cancer by blocking the programmed cell death protein 1 (PD-1) pathway. These drugs have transformed treatment for lung cancer, melanoma, head and neck ...

Lung cancer and malignant melanoma are major healthcare ... PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer.